| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Internet and Businesses Online > Email Marketing > Email Marketing Metrics - How To Measure the Success of Your Emails I |
|
Digg It - Email Marketing Metrics - How To Measure the Success of Your Emails I
When you are emailing, you must have a way to measure how effective your emails are, and what parts of your emails are more eff According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ective than others. Sure, you can evaluate an email by how many dollars it produces, but since many of your emails are going t ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in be content emails, this will be hard to implement across the board. Sometimes you can identify one single problem in your ema lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. il campaign, for example, a particular headline or email, and the responsiveness will go up for your entire campaign. Here are here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe some common email marketing metrics: Delivery Rates: The delivery rate is the percentage of emails that are actually delivere d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro . This is important, and by tracking these you can often determine either the effectiveness of your autoresponder service, and ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc you can determine if emails from certain sources have lower delivery rates – indicating that the quality of the lead or traffi easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi source is suspect. Open Rates: The open rate is the percentage of emails that are actually opened. This is one of my most i nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically mportant metrics for measuring email effectiveness. My email campaigns have anywhere from 5 to 20+ emails in them, plus I send and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ out a number of broadcasts, and for all of these, I track my open rates. I study the open rate degradation over time – noticin ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi particularly if one or two particular emails have an abnormally low open rate. This may indicate that the subject line or the ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a headline is not effective. If my email open rate drops dramatically and stays lows after one specific email, then I can assum dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod that one of the problems may be a bad email – one that actually turns so many people off that it lowers my open rate in subseq cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin uent emails. When you see this problem, take a look at the email immediately before the open rate drop occurs – is it a bad em tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen il? Does it promise something and doesn’t deliver? Send a test email of it to yourself, clicking through all the links and f t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel llowing all possibilities in the destination page. Perhaps it is a partner email and there is no follow through on the promise ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust . There are a number of open rate trackers out there, and many of the autoresponders provide automatic tracking. If you do no y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products have access to any of that, you can create an html image to put in your email; use a different one for each email, and you wil . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de l be able to look at your server logs to determine how many opens there are. To determine the open rate, simple divide the num elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip er of opens by the number of emails sent, and you have your open rate. For example: 25 opens, 100 emails 25 / 100 = .25 = 25 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Women Who Quit Work Abrubtly After Childbirth - Are You the Type? Top 7 Tips For Maximizing Your Education & Training Dollars to Deliver Positive Return on Investment
|